Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002
The collaborative effort, led by Amy E. DeZern, M.D., at the Johns Hopkins University School of Medicine, aims to advance development of ACLX-002, an immune cell therapy candidate directed at the therapeutic target CD123.
- The collaborative effort, led by Amy E. DeZern, M.D., at the Johns Hopkins University School of Medicine, aims to advance development of ACLX-002, an immune cell therapy candidate directed at the therapeutic target CD123.
- The collaboration includes research to be conducted by Craig Jordan, Ph.D., of the University of Colorado School of Medicine, and materials and expertise to be contributed by Arcellx.
- Patients with MDS face a poor prognosis despite current treatments, commented David Hilbert, Ph.D., President, Chief Executive Officer and Founder of Arcellx.
- Contact: Solebury Trout Zara Lockshin (media) Tel: +1 646-378-2960 Email: [email protected] Alan Lada (investors) Tel: +1 646-378-2927 Email: [email protected]